TY - JOUR
T1 - Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA
AU - Zhou, Chenhao
AU - Weng, Jialei
AU - Liu, Shaoqing
AU - Zhou, Qiang
AU - Hu, Zhiqiu
AU - Yin, Yirui
AU - Lv, Peng
AU - Sun, Jialei
AU - Li, Hui
AU - Yi, Yong
AU - Shen, Yinghao
AU - Ye, Qinghai
AU - Shi, Yi
AU - Dong, Qiongzhu
AU - Liu, Chunxiao
AU - Zhu, Xiaoqiang
AU - Ren, Ning
N1 - Publisher Copyright:
© 2023, Asian Pacific Association for the Study of the Liver.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Relapse of hepatocellular carcinoma (HCC) due to vascular invasion is common, but the genomic mechanisms remain unclear, and molecular determinants of high-risk relapse cases are lacking. We aimed to reveal the evolutionary trajectory of microvascular invasion (MVI) and develop a predictive signature for relapse in HCC. Methods: Whole-exome sequencing was performed on tumor and peritumor tissues, portal vein tumor thrombus (PVTT), and circulating tumor DNA (ctDNA) to compare the genomic profiles between 5 HCC patients with MVI and 5 patients without MVI. We conducted an integrated analysis of exome and transcriptome to develop and validate a prognostic signature in two public cohorts and one cohort from Zhongshan Hospital, Fudan University. Results: Shared genomic landscapes and identical clonal origins among tumor, PVTT, and ctDNA were observed in MVI (+) HCC, suggesting that genomic changes favoring metastasis occur at the primary tumor stage and are inherited in metastatic lesions and ctDNA. There was no clonal relatedness between the primary tumor and ctDNA in MVI (–) HCC. HCC had dynamic mutation alterations during MVI and exhibited genetic heterogeneity between primary and metastatic tumors, which can be comprehensively reflected by ctDNA. A relapse-related gene signature named RGSHCC was developed based on the significantly mutated genes associated with MVI and shown to be a robust classifier of HCC relapse. Conclusions: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.
AB - Background: Relapse of hepatocellular carcinoma (HCC) due to vascular invasion is common, but the genomic mechanisms remain unclear, and molecular determinants of high-risk relapse cases are lacking. We aimed to reveal the evolutionary trajectory of microvascular invasion (MVI) and develop a predictive signature for relapse in HCC. Methods: Whole-exome sequencing was performed on tumor and peritumor tissues, portal vein tumor thrombus (PVTT), and circulating tumor DNA (ctDNA) to compare the genomic profiles between 5 HCC patients with MVI and 5 patients without MVI. We conducted an integrated analysis of exome and transcriptome to develop and validate a prognostic signature in two public cohorts and one cohort from Zhongshan Hospital, Fudan University. Results: Shared genomic landscapes and identical clonal origins among tumor, PVTT, and ctDNA were observed in MVI (+) HCC, suggesting that genomic changes favoring metastasis occur at the primary tumor stage and are inherited in metastatic lesions and ctDNA. There was no clonal relatedness between the primary tumor and ctDNA in MVI (–) HCC. HCC had dynamic mutation alterations during MVI and exhibited genetic heterogeneity between primary and metastatic tumors, which can be comprehensively reflected by ctDNA. A relapse-related gene signature named RGSHCC was developed based on the significantly mutated genes associated with MVI and shown to be a robust classifier of HCC relapse. Conclusions: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.
KW - Circulating tumor DNA
KW - Hepatocellular carcinoma
KW - Microvascular invasion
KW - Relapse
KW - Whole-exome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85160096649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160096649&partnerID=8YFLogxK
U2 - 10.1007/s12072-023-10540-x
DO - 10.1007/s12072-023-10540-x
M3 - Article
C2 - 37217808
AN - SCOPUS:85160096649
SN - 1936-0533
VL - 17
SP - 1461
EP - 1476
JO - Hepatology International
JF - Hepatology International
IS - 6
ER -